Cellect Biotech jumps on deal for opioid-addiction drugs

Quoin Pharmaceuticals

04/03/2020 18:33

** U.S. shares of Israel-based stem cell therapy developer
 APOP.O  surge 37% to $2.85, erasing YTD losses 
    ** Company enters deal with InterCure Ltd's  INCR.TA  unit
Cannadoc to acquire the rights to use Cannadoc's drugs for
reduction in opioid usage  urn:newsml:reuters.com:*:nPn2zGLwNa
    ** Canndoc will supply Cellect with a minimum of 6 tons of
pharma-grade cannabis products over 5 years
    ** Cellect to issue Cannadoc $1 mln of its ADRs  
    ** Intercure has committed to invest cash of at least $3 mln
in any public offering that Cellect may undertake, at
least$4.50/ADR - APOP 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780,
outside U.S. +91 806749 2709;))